A simple, specific, and isocratic reversed phase-high performance liquid chromatography (RP-HPLC) method with UV detection at 293 nm and column Agela Technology, Venosil XBP C18, (Venosil XBP, 4.6mm×250mm, 10µm) was developed and validated for analysis of moxifloxacin hydrochloride (MOXI) in presence of its degradation products. The retention time of the MOXI was found at 9.99 min. A mobile phase consisting of phosphate buffer and methanol (18:7 v/v) at flow rate of 1.3mL/min, at temperature 50°C maintained by using column oven in the study. While 0.1N HCl was used as diluent. The calibration curves were linear with correlation coefficient (R2) of 0.999. The detection and quantification limit were found as 0.029 µg mL-1 and 0.095 µg mL-1 respectively. The method was validated in accordance with International Conference on Harmonization (ICH) guidelines. The proposed method was found sensitive, specific and was successfully applied for the estimation of MOXI in pharmaceutical formulations. Innumerable analytical measurements are made for the estimation of MOXI in pharmaceutical formulations, so the proposed analytical method leads to provision of cost effective by using low-cost diluents and the reagents.
Acid-catalyzed degradation limits the stability of many organic molecules, and its study often requires advanced instruments. This study shows how cyclic voltammetry, UV-vis spectroscopy, and density functional theory (DFT) calculations, available in most laboratories, can be combined to study such reactions, using murexide as a model system. The degradation of murexide, measured by the decrease in its cyclic voltammetric peak current, followed pseudo-first-order kinetics. The apparent rate constants were 0.0058, 0.0119, and 0.0343 min⁻¹, with half-lives of 119, 58, and 20 min at pH 4.9, 3.0, and 2.0, respectively. The UV-vis rate constant at pH 4.9 agreed with the electrochemical value. The large peak separation (730–742 mV) indicated slow electron transfer at the Pt electrode, with a transfer coefficient (α) of 0.32 and a heterogeneous electron transfer rate constant (k⁰) of (5.2 ± 0.2) × 10⁻4 cm s⁻¹. DFT calculations showed that protonation at the C5 carbon (calculated pKa ≈ 3.1) opens a low-energy hydrolysis pathway to alloxan and uramil. TDDFT analysis showed that the loss of the absorption at 510 nm is due to dis-ruption of the C5–N–C5 conjugation. This combined approach provides an accessible framework for studying acid-catalyzed degradation in research and teaching settings.
Iron sulfur clusters are essential cofactors of numerous proteins that play many important biological roles due to their unique reactivity—a product of their geometry, oxidation, and spin states. The geometry of the iron sulfur clusters of [4Fe-4S]2+ and [4Fe-4S]3+ in various spin states was investigated using density functional theory (DFT). Geometry optimizations and vibrational frequency calculations were carried out on these clusters using the B3LYP functional and the 6-311+G(d,p) basis set. The most stable spin state for the [4Fe-4S]2+ cluster was found to be the 19-et, an antisymmetric structure. The most stable spin state for the [4Fe-4S]3+ cluster was found to be the 20-et, also an antisymmetric structure. Interestingly, these cubane clusters consist of J aggregates of four species of FeS and FeS+. The breakage of a monomer FeS from a [4Fe-4S] cluster under different environments may be responsible for the observations of noncubane [4Fe-4S] clusters. Furthermore, with increased spin state, the positive and negative charges on the iron and sulfur increased and decreased, respectively, and the structure of cubane [4Fe-4S]2+ cluster evolves from the structure with a Fe tetramer as core and S as ligands to J-aggregate of FeS and to a homogeneous [4Fe-4S]2+ cluster.
Biowaiver is based on a Bio-pharmaceutical Classification System (BCS), and it is used to waive in-vivo studies of test products that are intended for registration from drug regulatory authorities. After certain in-vitro testing, the BCS tells whether the test product is “bioequivalent” to the reference or innovator product or not. Bioequivalence is needed to check the risks arising from the presence of different excipients in the formulation and due to manufacturing variables being deemed to be low. Moxifloxacin is a fluoroquinolone antibiotic drugs with a wide therapeutic index. It shows a broad spectrum of antibacterial activity against both Gram-positive and Gram-negative pathogens. Here, In-vitro biowaiver study of moxifloxacin was conducted based on Biopharmaceutical Classification System (BCS). Out of four BCS classes, moxifloxacin falls in class I which represents high solubility and high permeability. One innovator and five test brands of Moxifloxacin tablets were collected from the local market and their in-vitro dissolution study was performed by using pharma test DT 70 apparatus at different time (15, 30, 45 and 60 minutes), in three buffer systems i.e., hydrochloric acid buffer (pH 1.2), acetate buffer (pH 4.5) and phosphate buffer (pH 6.8). Biowaiver of moxifloxacin tablet is scientifically justified the dosage form of the reference product is rapidly dissolving (85% in 15 min) in all three buffers. Interestingly, we found low-cost alternative test products that show similar dissolution profiles to the reference product in these buffers. Therefore, the biowaiver study of moxifloxacin provides evidence that the test products are bioequivalent with innovator products which leads to provision of cost effective and alternative drug product.